Authors
Latest:
Unmet Needs Remain Unfilled in the Diffuse Large B-Cell Lymphoma SpaceThomas Habermann, MD, discusses the unmet clinical needs which still exist for patients with diffuse large B-cell lymphoma.
Latest:
Colorectal Cancer Awareness Month: Overcoming Barriers to Early DetectionCharles Meakin, MD, MHA, chief medical officer of Care Oncology, discusses the current colorectal cancer landscape, innovations in detection, and improving patient screening and follow-up care for Colorectal Cancer Awareness Month.
Latest:
Artificial Intelligence and Machine Learning in Cancer DetectionArtificial intelligence and machine learning dramatically alter how medicine is practiced, and cancer detection is no exception, according to Toufic Kachaamy, MD of City of Hope Phoenix.
Latest:
Daratumumab Regimen May Be the More Active Therapy Needed for AmyloidosisEfstathios Kastritis, MD, discusses the amyloidosis setting, current standards of care, and the phase 3 ANDROMEDA trial.
Latest:
Precise Management of EGFR exon 20-Positive Non–Small Cell Lung CancerResearch shows that methods used to treat the wide epidermal growth factor receptor-positive population are often not successful for patients with specific biomarkers like EGFR exon 20 insertion mutations, highlighting an ongoing need for more targeted therapies.
Latest:
Company-wide Initiative Will Provide Standards for Collection and StorageThe Florida Cancer Specialists & Research Institute's Data Governance Committee was established to oversee the program’s implementation and monitor its progress.
Latest:
Exploring The Donor-Derived CAR T-Cell Therapy, ALLO-501AMichael T. Tees, MD, discusses chimeric antigen receptor T-cell therapies, including ALLO-501A, and its use for patients with relapsed or refractory large B-cell lymphoma.
Latest:
Recent Trials Change Practice for Newly Diagnosed Multiple MyelomaPrerna Mewawalla, MD, a hematologist at Allegheny Health Network, discusses how her approaches to patients with newly diagnosed multiple myeloma have changed recently based on clinical trial outcomes.
Latest:
Olaparib Trial Supports 2-Year Treatment Duration in Ovarian CancerWilliam H. Bradley, MD, discusses the 5-year follow-up of the SOLO-1 trial of olaparib maintenance in patients with BRCA1/2-mutated advanced ovarian cancer.
Latest:
Addressing How to Treat Patients With Advanced Hepatocellular CarcinomaMehmet Akce, MD, discusses how he treats patients with advanced hepatocellular carcinoma in the first-line setting.
Latest:
Expanding the Use of Targeted Therapies in GISTNeeta Somaiah, MD, discusses the expanding role of targeted therapies in patients with gastrointestinal stromal tumor and how these treatments are bolstering later lines of therapy.
Latest:
Niraparib Results Encourage Somatic Tumor Profiling in Ovarian CancerMatthew Anderson, MD, PhD, discusses how the results with niraparib for patients with advanced ovarian cancer impacts the use of somatic profiling in this patient population.
Latest:
Challenges Remain in Treating Anaplastic Thyroid CancerYuliya Mikheeva, MD, PhD, discusses the many challenges oncologists face in treating patients with anaplastic thyroid cancer harboring BRAF mutations.
Latest:
Ibrutinib Plus Rituximab Data Surprising in Waldenstrom’s MacroglobulinemiaChristian Buske, MD, discusses surprising findings from the 5-Year follow-up of a randomized phase 3 trial in patients with Waldenström’s macroglobulinemia receiving of ibrutinib plus rituximab or placebo plus rituximab.
Latest:
Questioning When to Start Immunotherapy for Patients With Oncogenic DriversKaren Kelly, MD, discusses how oncogenic drivers affect the use and placement of immunotherapy for patients with lung cancer.
Latest:
Copanlisib and Rituximab Show Efficacy in Follicular LymphomaMark J. Roschewski, MD, discusses the preliminary results of a phase 2 trial of copanlisib and rituximab as treatment of patients with untreated follicular lymphoma.
Latest:
Lipe Discusses Therapeutic Options for a Patient With Transplant-Ineligible Multiple Myeloma"I think it’s important to know that this can change over time, what is defined as transplant eligibility, so getting the transplant center involved early can be helpful."
Latest:
Acute Lymphoblastic Leukemia in Older Adults: Is Chemotherapy-Free Treatment in the Future?Investigation of intensive chemotherapy regimens has unfortunately resulted in a lack of improvement in outcomes for patients with acute lymphoblastic leukemia in the second of the bimodal peaks.
Latest:
PARP Inhibition in Metastatic CRPC: The PROfound and TRITON2 StudiesExpert perspectives on the PROfound and TRITON2 studies of olaparib and rucaparib, respectively, in metastatic castration-resistant prostate cancer.
Latest:
Skin Toxicity in Cancer Treatment: A Critical Part of Cancer Supportive CareIn contrast to the innovations in cancer treatments that help drive improved survival, there are far fewer innovations targeting toxicities and providing supportive care.
Latest:
Phase 3 ADAURA Study Highlights Role for Precision Medicine in EGFR-Positive NSCLCMasahiro Tsuboi, MD, discusses the findings from the phase 3 ADAURA clinical trial of osimertinib as treatment of patients with EGFR-mutated non–small cell lung cancer.
Latest:
MRD Linked to Long-Term Survival With Azacitidine Therapy in AMLAndrew Wei, MBBS, PhD, discusses outcomes related to long-term survival in the QUAZAR AML-001 trial of oral azacitidine in patients with acute myeloid leukemia.
Latest:
Future Directions for NK Cell Platforms in Hematologic MalignanciesJeffrey Miller, MD, discusses what is next to come following an analysis of GTB-3550.
Latest:
Manipulating T Cells to Treat Patients With CancerBruce Feinberg, DO, explains how chimeric antigen receptor T cells were introduced in hematologic malignancies.
Latest:
Closing Thoughts on the GVHD Treatment LandscapeNelson J. Chao, MD, offers closing thoughts on his treatment approach for a 35-year-old woman with chronic GVHD, and looks to the future of GVHD treatment.
Latest:
What’s Next for the HER2-Negative Breast Cancer Space?Evanthia Roussos Torres, MD, PhD, discusses the next steps and novel therapies currently showing promise in the HER-2 negative breast cancer space.
Latest:
Addressing Toxicities of BCMA-Targeted Therapy for Multiple MyelomaAdam Cohen, MD, discusses the adverse events of concern associated with B-cell maturation antigen–targeted therapies for relapsed/refractory multiple myeloma.
Latest:
Villaruz Discusses Updates in Biomarker-Driven Lung CancerLiza C. Villaruz, MD, discusses the latest areas of growth in the non–small cell lung cancer space.
